---
title: "Enzyme Replacement Therapy Medicines"
ocid: "ocds-r6ebe6-0000774962"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000774962"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000774962.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000774962.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (\"NSS\")"
published: "2024-08-15"
---

# Enzyme Replacement Therapy Medicines

Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("NSS")  
Current stage: Award  
OCID: ocds-r6ebe6-0000774962

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000774962)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000774962.json)

## Summary

The Common Services Agency, also known as NHS National Services Scotland (NSS), has concluded a procurement process for the supply of Enzyme Replacement Therapy Medicines to NHS Scotland. This contract, categorised under the health industry, involves the provision of various enzyme replacement products such as Aldurazyme®, Cerezyme®, Fabrazyme®, and Myozyme®. The award stage was completed with a contract signed on July 18, 2024, and the procurement was performed using a limited method due to the protection of exclusive intellectual property rights. The medicines will be supplied by Aventis Pharma Ltd Trading as Sanofi and the contract has an estimated value of £12,437,853. The delivery will cover all entities under the National Health Service (Scotland) Act 1978, primarily in the UKM region.

This procurement provides a significant business growth opportunity for pharmaceutical companies and suppliers who specialise in rare or specialized medical treatments. While this particular tender was awarded without a competitive call for competition due to intellectual property rights, similar future opportunities could be pursued by businesses holding exclusive rights to innovative health solutions. Large-scale suppliers with niche pharmaceutical products, robust supply chain capabilities, and the ability to meet stringent regulatory requirements would be well-positioned to compete in such high-value procurement contracts.

## Notice

Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme(r)) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme(r)) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme(r)) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme(r)) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme(r))

### Lot Information

Lot 1

The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (a-d: Aldurazyme(r)/ Cerezyme(r)/ Fabrazyme(r)/ Fabrazyme(r)/ Myozyme(r)) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.

### Procurement Information

The medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG512133 |
| Notice type | OJEU - F3 - Contract Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 15 Aug 2024 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 18 Jul 2024 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £12,437,853 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("NSS") |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH12 9EB |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | Drum Brae/Gyle |
| Westminster constituency | Edinburgh South West |
| Delivery location | TLM Scotland |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | AVENTIS PHARMA LTD TRADING AS SANOFI |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 15 Aug 2024 at 00:00 - Award - OJEU - F3 - Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG512133

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG512133
  Enzyme Replacement Therapy Medicines - Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme(r)) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme(r)) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme(r)) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme(r)) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme(r))

## Notice URLs

- http://
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000774962

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000774962. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000774962.json.